Susquehanna International Group LLP Increases Holdings in Nautilus Biotechnology, Inc. $NAUT

Susquehanna International Group LLP grew its position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 1,710.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 890,949 shares of the company’s stock after buying an additional 841,749 shares during the period. Susquehanna International Group LLP owned 0.70% of Nautilus Biotechnology worth $1,666,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of NAUT. Virtu Financial LLC lifted its stake in Nautilus Biotechnology by 19.6% during the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after acquiring an additional 3,849 shares in the last quarter. Bridgeway Capital Management LLC grew its holdings in Nautilus Biotechnology by 4.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock worth $254,000 after acquiring an additional 5,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Nautilus Biotechnology by 2.2% during the first quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock worth $1,031,000 after purchasing an additional 5,800 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Nautilus Biotechnology by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock valued at $1,094,000 after acquiring an additional 7,307 shares during the last quarter. Finally, CTC Alternative Strategies Ltd. purchased a new position in Nautilus Biotechnology in the first quarter valued at approximately $48,000. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.00.

Insider Activity at Nautilus Biotechnology

In other news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the transaction, the insider directly owned 971,885 shares of the company’s stock, valued at $2,283,929.75. This trade represents a 83.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 41.10% of the stock is owned by corporate insiders.

Nautilus Biotechnology Stock Performance

NAUT stock opened at $0.89 on Monday. The company’s 50-day moving average price is $1.41 and its 200 day moving average price is $2.26. The company has a market cap of $112.71 million, a P/E ratio of -1.97 and a beta of 0.87. Nautilus Biotechnology, Inc. has a 52 week low of $0.62 and a 52 week high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Tuesday, July 28th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.